Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 34,700 shares, an increase of 38.8% from the February 28th total of 25,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Oculis in the fourth quarter valued at approximately $389,000. Bank of America Corp DE increased its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after acquiring an additional 10,667 shares in the last quarter. Bellevue Group AG acquired a new position in Oculis during the fourth quarter worth $170,000. XTX Topco Ltd purchased a new position in Oculis during the fourth quarter valued at $225,000. Finally, Geode Capital Management LLC grew its position in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Trading Down 1.1 %

NASDAQ OCS opened at $19.18 on Monday. The stock has a market cap of $837.44 million, a P/E ratio of -9.94 and a beta of 0.01. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08. The company has a fifty day simple moving average of $20.66 and a two-hundred day simple moving average of $17.52.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $28.00 target price on shares of Oculis in a report on Thursday, March 13th. Robert W. Baird lifted their price objective on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, March 13th. Finally, HC Wainwright cut their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.